Frumm SM, Fan ZP, Ross KN, et al. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol. 2013;20(5):713-25. doi:10.1016/j.chembiol.2013.03.020
Dunn GP, Cheung HW, Agarwalla PK, et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A. 2014;111(3):1102-7. doi:10.1073/pnas.1311909111
Del Vecchio CA, Feng Y, Sokol ES, et al. De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling. PLoS Biol. 2014;12(9):e1001945. doi:10.1371/journal.pbio.1001945
Jiang P, Freedman ML, Liu JS, Liu XS. Inference of transcriptional regulation in cancers. Proc Natl Acad Sci U S A. 2015;112(25):7731-6. doi:10.1073/pnas.1424272112
Zheng S, Cherniack AD, Dewal N, et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016;29(5):723-36. doi:10.1016/j.ccell.2016.04.002
Kim SY, Dunn IF, Firestein R, et al. CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One. 2010;5(2):e8979. doi:10.1371/journal.pone.0008979
Pegtel M, Subramanian A, Meritt D, et al. IFN-alpha-stimulated genes and Epstein-Barr virus gene expression distinguish WHO type II and III nasopharyngeal carcinomas. Cancer Res. 2007;67(2):474-81. doi:10.1158/0008-5472.CAN-06-1882
Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-7. doi:10.1038/nature11003
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43-9. doi:10.1038/nature12222
Knoechel B, Roderick JE, Williamson KE, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46(4):364-70. doi:10.1038/ng.2913